Evidence record · ER-RETATRUTIDE-RECORDS-034
Grey-market retatrutide: what a medical-record preprint can show
Claim assessed: This medical-record preprint verifies a retatrutide product or establishes its causal effects.
Retatrutide use reported in US health records is the focus of a preprint by Murugadoss and colleagues. This early paper has not been peer reviewed. The team did not test products. Its reported weight and symptom differences do not prove that a vial caused a health problem. Murugadoss et al., 2026
These fields assess the claim stated above. They do not score the quality of an individual laboratory measurement or confirm a seller’s product.
What was counted?
The preprint found 652 people recorded as users. The source was known for 531; 378 obtained products said to contain retatrutide outside trials. They must not all be described as 652 confirmed grey-market users. Study population
Why are the comparisons uncertain?
Unclear start dates, earlier drug use and uneven follow-up limit the comparisons. The trial records could not separate active drug from placebo. There were too few major heart or vascular events to draw a sound risk conclusion. Methods and limitations
Who produced the analysis?
The authors work for nference, which has drug-company research links. They declared no outside funding or role for those partners in the study. Declarations
How does this differ from checking a vial?
A health record and a lab report answer different questions. A note of what someone took helps with care. It cannot show what the product contained. Our testing guide explains the tests and sample details needed to check a vial.
| Evidence object | Question it can address |
|---|---|
| A clinical record | What was documented about a person’s exposure and health? |
| A sample-linked test | What did the stated method measure in that sample? |
| A controlled clinical trial | What outcomes followed the assigned intervention under its protocol? |
Our retatrutide profile keeps the treatment trials separate. What’s in the Vial? does not turn a reported product name into a known ingredient. The gap between those two things is the reason for this record. It belongs with evidence about the supply route; it does not replace a trial.
What is the relevance for UK readers?
The MHRA’s 24 July 2026 warning states that retatrutide is not authorised in the UK. Products sold under its name may not contain it. A US study of health records does not change that status or tell us what a UK seller’s product contains. MHRA warning
The Yellow Card scheme accepts reports of suspected side effects and faulty medicines. It does not give medical advice. Seek care if you feel unwell. Our urgent warning-signs page explains when to use NHS 111 or call 999. Do not wait for a report or a product check before seeking urgent help.
Sources and review history
- Murugadoss et al. · version 1 · 18 August 2026 · not peer reviewed
- MHRA warning · 24 July 2026
- UK Yellow Card reporting route
Preprint version 1, declarations and the linked official UK guidance checked. The preprint remains unreviewed by the journal peer-review process. Source check: 6 September 2026. Published 6 September 2026. Recheck by 6 March 2027, or earlier after a correction, new version, peer-reviewed publication or relevant regulatory change.